Bradley Merrill Thompson, Strategic Advisor with EBG Advisors and Member of the Firm in the Health Care & Life Sciences practice at Epstein Becker Green, was mentioned in BioWorld, in “FDA Draft for Digital Tech in Clinical Trials Languishes Despite Agency’s Digital Push,” by Mark McCarty. (Read the full version – subscription required.)
Following is an excerpt:
The U.S. FDA’s formation of the Digital Health Center of Excellence (DHCoE) was heralded as a key enabler of digital health technologies, but the news hasn’t necessarily had the expected effect. The agency’s December 2021 draft guidance on the use of digital health technologies to assist in the conduct of clinical trials is still in regulatory drydock. …
Writing for the coalition was Brad Thompson of Epstein Becker Green, who said the scope of the guidance should include any DHTs that might be used by …
